| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the U 451 INSERM (Dr. Coirault), Laboratoire d’Optique Appliquée-ENSTA-Ecole Polytechnique, Palaiseau; Service de Cardiologie (Dr. Hagège and Guérot), Hôpital Boucicaut, Paris; Service d’Explorations Fonctionnelles (Drs. Chemla and Lecarpentier), Centre Hospitalier et Universitaire de Bicêtre, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre; and IRIS (Dr. Fratacci), Courbevoie, France.
Correspondence to: Catherine Coirault, MD, PhD, INSERM 451-LOA-Ensta-Ecole Polytechnique, Batterie de l’Yvette, 91761 Palaiseau Cedex, France; e-mail: coirault{at}enstay.ensta.fr
Study objectives: Respiratory muscle strength has been shown to be reduced in patients with chronic heart failure. The purpose of this prospective study was to determine whether long-term therapy with the angiotensin-converting enzyme (ACE) inhibitor perindopril improves respiratory muscle strength in patients with chronic heart failure.
Patients and methods: Eighteen patients with stable chronic heart failure were administered perindopril, 4 mg/d, in addition to their standard therapy for a period of 6 months. Fourteen patients completed the study. Maximum inspiratory pressure (PImax) and maximum expiratory pressure (PEmax) expressed in percentage of predicted values, left ventricular ejection fraction (LVEF) determined by means of two-dimensional echocardiography, and pulmonary volumes were obtained before and after therapy.
Measurements and results: As
compared to baseline, there was a significant increase in both
PImax and PEmax after therapy (57 ± 27%
predicted vs 78 ± 36% predicted and 62 ± 20% predicted vs
73 ± 15% predicted, respectively; each p < 0.05). LVEF increased
(34 ± 5% vs 41 ± 10%; p < 0.05); functional class improved
by 
1 New York Heart Association (NYHA) class in five patients.
There were no changes in pulmonary volumes. No correlation was found
between changes in PImax and PEmax and changes
in either LVEF or NYHA functional class.
Conclusions: In patients with chronic heart failure, long-term therapy with the ACE inhibitor perindopril improved respiratory muscle strength, as indicated by significant increases in PImax and PEmax.
Key Words: angiotensin • heart failure • respiratory muscles
This article has been cited by other articles:
|
|
 |
|
  S. Andreas, C. Herrmann-Lingen, T. Raupach, L. Luthje, J. A. Fabricius, N. Hruska, W. Korber, B. Buchner, C-P. Criee, G. Hasenfuss, et al. Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial Eur. Respir. J., May 1, 2006; 27(5): 972 - 979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G Burniston, A. Saini, L.-B. Tan, and D. F Goldspink Angiotensin II induces apoptosis in vivo in skeletal, as well as cardiac, muscle of the rat Exp Physiol, September 1, 2005; 90(5): 755 - 761. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. White, N. Terrin, K. B. Miller, and H. F. Ryan Impaired Respiratory and Skeletal Muscle Strength in Patients Prior to Hematopoietic Stem-Cell Transplantation Chest, July 1, 2005; 128(1): 145 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Forth and H Montgomery ACE in COPD: a therapeutic target? Thorax, July 1, 2003; 58(7): 556 - 558. [Full Text]
|
|
|
|
|
|
H. Kanazawa, T. Otsuka, K. Hirata, and J. Yoshikawa Association Between the Angiotensin-Converting Enzyme Gene Polymorphisms and Tissue Oxygenation During Exercise in Patients With COPD Chest, March 1, 2002; 121(3): 697 - 701. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
